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nanomedjournal.comAbstract
C109 is a potent but poorly soluble FtsZ inhibitor displaying promising activity against Burkholderia cenocepacia, a high-risk pathogen
for cystic fibrosis (CF) sufferers. To harness C109 for inhalation, we developed nanocrystal-embedded dry powders for inhalation
suspension consisting in C109 nanocrystals stabilized with D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) embedded in
hydroxypropyl-β-cyclodextrin (CD). The powders could be safely re-dispersed in water for in vitro aerosolization. Owing to the presence of
a PEG shell, the rod shape and the peculiar aspect ratio, C109 nanocrystals were able to diffuse through artificial CF mucus. The promising
technological features were completed by encouraging in vitro/in vivo effects. The formulations displayed no toxicity towards human
bronchial epithelial cells and were active against planktonic and sessile B. cenocepacia strains. The efficacy of C109 nanosuspensions in
combination with piperacillin was confirmed in a Galleria mellonella infection model, strengthening their potential for combined therapy of
B. cenocepacia lung infections.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the formation of thick and sticky mucus in the lungs, leading to
serious infections in CF sufferers, with chronic inflammation,
progressive lung damage, and premature death.1 To extend
the life expectancy of CF patients, it is mandatory to control
infections and inflammation.2,3 Nonetheless, CF pathogens are
naturally multidrug resistant to antibiotics and can form biofilms
in the airways, thus increasing their tolerance to drugs.2 ,3⁎Corresponding authors.
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Burkholderia cenocepacia is a Gram-negative bacterium that
causes an increased decline of lung function and potential fatal
pneumonia.4 B. cenocepacia shows resistance to numerous classes
of antibiotics.5 Moreover, patients colonized by B. cenocepacia
show 50% lower post-transplant survival than non-colonized
people,6 so often they are not admitted to transplant.7 In general,
the use of combined therapy is recommended,8 but standardized
eradication protocols do not exist.9
Despite the high levels of resistance, there has been little
progress in developing new therapeutic strategies to fight
B. cenocepacia infections. In previous studies, a new benzothia-
diazole derivative, named C109, was found to have a promisingunder theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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recently, C109 was demonstrated to act as an inhibitor of the
filamenting temperature-sensitive mutant Z (FtsZ) protein,11
involved in the bacterial cell-division process.12
The proven anti-burkholderia activity of C109 makes this
compound an interesting candidate for local treatment of lung
infections in CF patients, who strongly benefit of aerosolized
antibacterial therapies.13 Nevertheless, inhaled C109 poses impor-
tant formulation and delivery challenges because of its poor
aqueous solubility. Among the available formulation options, the
so-called “nanosuspensions” are colloidal dispersions of pure sub-
micron drug particles stabilized by surfactants (i.e., nanocrystals)
that can help to increase drug solubility and dissolution rate in
biological fluids.14,15 For pulmonary application, an aqueous
nanosuspension can be delivered through commercially available
nebulizers.16 Nonetheless, the ability of the drug nanocrystals to
adequately deposit along the airways and to overcome extracellular
lung barriers should be taken properly into account.17,18 In this
respect, numerous lines of evidence suggest that PEGylation may
improve penetration of the nanoparticulate system inside both
mucus and bacteria biofilm lining airway epithelia.19–21 In addition,
size and shape are relevant parameters governing deposition and
fate within biological environments.22,23
The aim of this work was the development of inhalable
nanosuspensions consisting in C109 nanocrystals stabilized with
D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS).
Optimized formulations (i.e., TPGS_C109) were freeze-dried
with hydroxypropyl-β-cyclodextrin (CD), which has been previ-
ously demonstrated a valid cryoprotectant for PEGylated
nanoparticles.24 The developed formulations were fully charac-
terized, paying attention to C109 nanocrystal structure, aerosol
performance, interactions with mucus and in vitro/in vivo efficacy.Methods
All the details of the listed methods are reported in the
Supplementary Data.
Materials
All chemicals and reagents are described in Supplementary
Data. Methyl [(4-nitro-2,1,3-benzothiadiazol-5-yl)thio]acetate
(10,126,109; C109) was synthesized and characterized at as
previously reported.10
Production and characterization of C109 nanosuspensions
C109 nanosuspensions were produced by nanoprecipitation.
C109 (5-10 mg) was solubilized in 1 ml of organic solvent,
loaded into a syringe and injected dropwise in 10 mL of aqueous
TPGS (10-20 mg). The resulting dispersion was transferred
in ice and sonicated by a microtip probe for 6 min at 1 W
(Sonicator 3000, Misonix, USA). Afterwards, the organic
solvent was removed under stirring overnight and the dispersion
diluted to 10 mL with ultrapure water. When appropriate, the
nanosuspension was centrifuged at 1000 rpm for 5 min (Hettich
Zentrifugen, Universal 16R).The hydrodynamic diameter (DH), the polydispersity index
(PDI) and the zeta potential (ζ) of the nanosuspensions were
determined with a Zetasizer Nano ZS (Malvern Instruments,
UK). C109 concentration was determined by UV–vis spectro-
photometry after solubilizing an appropriate volume of nano-
suspension in tetrahydrofuran.
Production and characterization of C109 nanocrystal-embedded
dry powders
After addition of CD at 0.5 or 1% (w/v), optimized C109
nanosuspensions (TPGS_C109) were freeze-dried at 0.1 mbar
and −80 °C (LyoQuest, Telstar Italy).
DH, PDI and the ζ of the reconstituted nanosuspensions were
determined. Nanocrystal shape and morphology were analyzed
by transmission electron microscopy (TEM) upon air drying
10 μL of reconstituted nanosuspension (3 mg/ml) mounted on
200 mesh copper grids coated with carbon film. The analysis was
performed with a FEI Tecnai G2 200 kV s-Twin microscope
equipped with a 4 K camera (ThermoFisher Scientific, US).
Fixed aqueous layer thickness (FALT) of the nanocrystals was
evaluated before and after freeze-drying by monitoring the
influence of NaCl (final concentration 1-15 mM) on the ζ of
nanocrystals.25
Scattering methods
Small-angle and wide-angle x-ray scattering
TPGS_C109 nanosuspension and the corresponding freeze-
dried powders were investigated at room temperature by
combining small-angle (SAXS) and wide-angle X-ray scattering
(WAXS) experiments. The measurements were carried out at the
ESRF high brilliance SAXS beamline ID02 (Grenoble,
France).26
Small-angle neutron scattering
Small-angle neutron scattering (SANS) experiments were
performed at the Institut Laue-Langevin, ILL (Grenoble, France)
using the D33 diffractometer.
In vitro aerosol performance
In vitro aerosolization properties of C109 nanocrystal-
embedded dry powders for inhalation suspension were tested
after delivery from different commercial nebulizers: PARI
TurboBOY® (PARI GmbH, Germany), eFlow® rapid (PARI
GmbH, Germany) and Aeroneb® Go (Aerogen, Ireland). The
deposition pattern was investigated using a Next Generation
Impactor (NGI) (Copley Scientific, UK),with sampling at 15 L/min
and insertion of a filter in micro-orifice collector (MOC) as
previously reported.27
Studies in simulated lung fluids
Simulated lung fluids composition and preparation
Simulated interstitial lung fluid (SILF) was prepared
according to Marques et al.28 The artificial CF mucus was
achieved as previously reported.27 A mucin type II dispersion
(2% w/v) in salt-containing D2O (4.4 mg/mL sodium chloride,
15 mg/mL potassium chloride and 3.0 mg/mL calcium chloride
dehydrate) was also prepared for SANS measurements.
Table 1
Overall properties of C109 nanocrystals.
TPGS_C109 TPGS_C109_
CD0.5
TPGS_C109_
CD1.0
DH
1 (nm ± SD2) 823 ± 123 931 ± 111 842 ± 162
PDI1 (A.U. ± SD2) 0.331 ± 0.098 0.353 ± 0.075 0.382 ± 0.075
Zeta potential1
(mV ± SD2)
−21.2 ± 6.07 −21.8 ± 6.02 −20.1 ± 3.19
RDI3 (A.U. ± SD2) - 1.166 ± 0.091 0.980 ± 0.073
C109 (mg/mL ± SD2) 0.568 ± 0.132 - -
C109 (% ± SD2) - 7.16 ± 1.17 2.79 ± 0.361
1 Values determined by dynamic light scattering (DLS) and electrophoretic light
scattering (ELS) with the Zetasizer Nano ZS (Malvern Instruments Ltd., UK).
2 Results are expressed as mean value ± standard deviation (SD) of values
collected from 3 batches (n = 3).
3 Redispersibility index (RDI) is defined as DHi/DHf where DHi is the mean
size of the nanosuspension prior to drying, and DHf is the corresponding value
post-rehydration of the dried sample in water.
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mucus
For SAXS measurements, a nanocrystal dispersion in water
(10 mg/mL) was mixed with artificial CF mucus (1:3 v/v).
Measurements were performed after 1 h equilibration time.
SAXS studies of particle horizontal migration in artificial CF
mucus were performed in the same plastic capillaries used for
structural investigation by inserting 80 μL of mucus from one
edge of the capillary and 20 μL of the particle dispersion from
the other edge, to put them in contact inside the capillary (total
interface 3.14 mm2). Capillaries were kept horizontally, and
spectra were taken during 10 h in different horizontal positions
along the capillary.
For SANS measurements, the nanocrystal dispersion at
10 mg/mL was mixed with the mucin type II dispersion in salt
containing D2O (1:3 v/v). The spectra lag time after preparation
was around 5 h.
C109 release in simulated lung fluids
In vitro release studies of C109 from artificial CF mucus
to SILF were performed by membrane dialysis as previously
reported.27 Briefly, C109, TPGS_C109 (0.1 mL) or a corre-
sponding amount of TPGS_C109_CD0.5/TPGS_C109_CD1.0
was added to 0.3 mL of artificial mucus or PBS and transferred
in a dialysis bag (MWCO: 5000 Da, Spectra/Por®). Each sample
was placed into 5 mL of external medium and kept at 37 °C.
At scheduled time intervals, 1 mL of the external medium
was withdrawn, replaced by the same amount of fresh medium
and analyzed for C109 content. Triplicate experiments were
performed.
In vitro antimicrobial activity
The MICs of the C109 formulations for B. cenocepacia
J2315 (LMG 16656), K56-2 (LMG 18863), B. cenocepacia
clinical isolates, Escherichia coli (ATCC 25922), Acinetobacter
baumannii (ATCC 19606), Klebsiella pneumoniae (ATCC
13883), and Staphylococcus aureus (ATCC 25923) were
determined by the microdilution method followed by resazurin
colorimetric assay.29
Inhibitory and eradication activity of B. cenocepacia J2315
biofilm was evaluated as described in Supplementary Data.
Cytotoxicity on human bronchial epithelial cells
The viability of human bronchial epithelial cells wild type
(16HBE), or homozygous for ΔF508 mutation (CFBE41o-)
upon exposure to the formulations was assayed using the MTT
method.30
In vivo antimicrobial activity
LD50 B. cenocepacia K56-2 (103 CFU/larva)31 was injected
into G. mellonella (Decathlon, www.decathlon.it). Larvae were
divided in different groups receiving a 10-μL injection of: C109
dissolved in DMSO (20 mg/kg); TPGS_C109 (20 mg/kg);
TPGS (at equivalent concentrations); piperacillin (100 mg/kg),
TPGS_C109 plus piperacillin or the vehicles (saline or DMSO).
After treatment, larvae were placed in Petri dishes in the dark
at 30 °C, and scored as dead or alive after 24 h, 48 and 72 h.Results
Development of C109 nanocrystal-embedded dry powders
In depth formulation studies were devoted to the development
of C109 nanocrystal-based dry powders to be reconstituted
in aqueous medium for inhalation suspension. First, aqueous
dispersions of drug nanocrystals were produced by a nanopre-
cipitation technique. Three variables were considered: drug
solvent, C109 concentration and type of stabilizer. Optimal
formulation parameters were chosen based on size, PDI and ζ
of the nanocrystals. Of note, unreliable data were acquired by
dynamic light scattering when using DMSO or THF as solvents,
independently on C109 concentration (Table S1). The particle
size distribution, as determined by laser diffraction analysis,
confirmed the micrometric dimensions of the crystals, displaying
D90 ~4.5 μm. The use of ethanol at 60 °C reduced particle size,
though crystals with DH higher than 1 μm were still achieved
(Table S1). Nanocrystal size further increased when using hot
ethanol as solvent in the presence of Pluronic® F68 as co-stabilizer
either in the water or in the organic phase (D90 b 10.9 μm and
D90 b 6.9 μm, respectively). The nanosuspension achieved by
nanoprecipitation of a C109 hot ethanol solution in aqueous
TPGS (C109/TPGS 1:2 w/w) was selected as the best candidate
for further experiments. A centrifugation step allowed to select
nanocrystals with a DH of 823 ± 123 nm, acceptable PDI (~0.3)
and negative ζ (Table S1).
To improve the stability of optimized TPGS_C109 nanosus-
pension, nanocrystal-embedded dry powders were produced by
freeze-drying. When the nanocrystals underwent the lyophiliza-
tion process, massive particle aggregation was observed; thus,
CD was selected as cryoprotectant to be added before freeze-
drying. The composition and the overall properties of the C109
formulations are listed in Table 1.
CD was added just after production to the aqueous phase
of the nanosuspension at 0.5 or 1.0% w/v. In both cases,
no significant differences in PDI and zeta potential of the
nanosuspension before and after freeze-drying were observed
(Table 1). A slight increase in the value of DH was observed
upon rehydration of TPGS_C109_CD0.5 as compared to both
Figure 1. (A) SAXS spectra of TPGS_C109 (orange squares),
TPGS_C109_CD0.5 (red triangles) and TPGS_C109_CD1.0 (blue circles).
The black line is the fit of the lowest q region by a generalized Guinier-
Porod model. The free TPGS (dotted line) and the free CD (dashed line)
spectra are reported with arbitrarily rescaled intensity for the sake of
comparison. (B) WAXS spectra of raw C109 crystals (top) and the
C109 contribution to the WAXS spectrum of the TPGS_C109_CD1.0
nanosuspension (bottom). The nanocrystal contribution to the WAXS
intensity was obtained after subtraction of water, TPGS and CD
contributions in the right proportions. Large undulation is due to imperfect
subtraction (note that C109 contribution is of the order of 1% in intensity
after water subtraction). Vertical scales are arbitrary, and intensities are
rescaled. (C) SANS spectra of TPGS_C109 (orange triangles), and
TPGS_C109_CD1.0 (blue squares).
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the RDI value is always around 1. Of note, HPLC-MS analysis
confirmed that C109 was stable over the production process
(Figure S1).
Structural characterization of C109 nanocrystals
SAXS and WAXS measurements were performed to
elucidate the structure of C109 nanocrystals. The measured
SAXS profiles of the 1% w/v dispersion are reported in Figure 1,
A along with those of free TPGS and CD for comparison. The
high q portion of the scattering profiles was mainly contributed
by free TPGS micelles and CD (when present). Of course, the
TPGS_C109 spectrum (orange squares in Figure 1, A) clearly
shows the lack of the CD contribution at high q. To devise
this interpretation, the complementary SANS investigation is
relevant (Figure 1, C). The investigated SANS spectral range
is dominated by the scattering from the residual free TPGS
micelles, with an increased scattering intensity at q N 1 nm−1 for
the TPGS_C109_CD1.0 due to the presence of CD. SANS
results, in agreement with previous studies elucidating TPGS
core-shell structure,32 suggest that CD did not affect micelle
structure (Figure S2). Indeed, when reconstructing the high-q
SAXS profile by summing the different contributions in proper
proportion, it is possible to estimate that the amount of residual
free TPGS in TPGS_C109_CD1.0 is about 13% w/w (about one-
half of the total amount added in solution) and the amount of free
CD is 72% w/w. Balancing the known added weights in the
formulation, the nanocrystal is estimated to contribute 16% w/w
to the total powder (Figure S3). To determine the structure
of the nanocrystal, we consider the scattering intensity in the
intermediate and low-q regions of the spectra.
A first analysis of SAXS measurements using a generalized
Guinier-Porod model33 gives evidence of the presence of large-
sized and elongated-shaped structures (Table S2). The dimen-
sionality (3 − s) of the structure was obtained ~2, denoting rod-
like particles. The gyration radius Rg was around 100 nm. The
Porod exponent ~4 is distinctive of the scattering from dispersed
particles, allowing to interpret the total scattering spectrum as the
sum of the scattering from the large particles (the nanocrystal),
free TPGS and CD. Both SAXS (Figure 1, A) and SANS
(Figure 1, C and S2, B) measurements give a Porod exponent
of ~3.8 (i.e. 3 ≤ P ≤ 4), that is distinctive of surface fractal
structures with low roughness. For all the formulations, the
particle size is not strongly affected by the presence of CD (also
shown by the overlapping of the spectra of the three formulations
at low q). Although very low scattering vectors are obtained
at 10 m sample-detector distance, still some limitation to the
analysis arises due to the size polydispersity (PDI ~0.3) of
the nanocrystal, including quite long aggregates even below the
acquired q range (see Supplementary Data).
Contemporary acquiredWAXS spectra confirmed the presence
of C109 crystal peaks in the formulations. Figure 1, B reports the
representative WAXS spectra of C109 and TPGS_C109_CD1.0,
which were obtained from the spectrum of the entire nanosuspen-
sion by subtraction of water, CD and TPGS contributions. Sharp
peaks corresponding to those of the C109 crystal intramolecular
ordering are apparent.
Figure 2. (A) TEM images of TPGS_C109_CD0.5 and TPGS_C109_CD1.0 nanocrystals after redispersion in water (field is representative of the sample). (B) FALT
measurements of the PEG shell thickness of C109 nanocrystal formulations. The slopes of the linear regressions indicate the corresponding shell thickness in nm.
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C109_CD1.0 after redispersion in water confirmed a polydis-
perse population of elongated rod-shaped particles (Figure 2, A).
The presence of a PEG shell on the surface of nanocrystals was
confirmed by FALT measurements performed by monitoring
the influence of ionic strength of the dispersing medium on
particle surface charge as previously reported.25,34 According to
the Gouy-Chapmann theory, zeta-potential (ζ) decreased with
increasing of the ionic strength of the medium. A plot of ln (ζ)
against k (k = 3.3 c0.5, where k−1 is the Debye length) gives the
thickness of the PEG polymer layer in nm as the slope of a linear
regression (Figure 2). Interpolation indicates that a shell of
3.9 nm is formed on the surface of C109 nanocrystals, this value
slightly increasing in the presence of CD (FALT around 4.56 nm).
In vitro aerosolization properties of C109 nanocrystal-embedded
dry powders
Results achieved upon in vitro aerosolization of TPGS_
C109_CD0.5 and TPGS_C109_CD1.0 through NGI after
reconstitution of the nanosuspensions in water are reported in
Figure 3.
Both TPGS_C109_CD0.5 and TPGS_C109_CD1.0 were first
delivered using an advanced and handy nebulizer relying on the
vibrating mesh technology (VMT) already employed in clinical
practice: Aeroneb® Go (Aerogen, Ireland). Figure 3, A describes
the cumulative droplet size distribution of the emitted dose. In both
cases, the best fit line was from logarithmic linear regression
(r2 ≥ 0.98). High fine particle fractions (FPF ~40%) and low
values of experimental mass mean aerodynamic diameter
(MMADexp ~3 μm)were calculated, independently onCD amount
in the formulation. Also, the deposition pattern of C109 throughout
the NGI cups was very similar for TPGS_C109_CD0.5 and
TPGS_C109_CD1.0 (Figure 3, B). A homogeneous distribution
of the formulation throughout the seven NGI stages down to
MOC was observed, with a maximum amount of the drug
recovered from cups 3 and 4 (MMAD 5.39-3.3 μm).
Aerodynamic assessment of fine particles of TPGS_C109_
CD1.0 was performed also after delivery from differentcommercial nebulizers available to CF patients, both conven-
tional jet (i.e., PARI TurboBOY®) and VMT (i.e., eFlow®
Rapid) nebulizers. Notably, the reconstituted C109 nanosuspen-
sion displayed good aerosol performance independently of the
adopted nebulizer (Figure 3, B). Corresponding fine particle
characteristics of the aerosol clouds are reported in Table 2.
MMADexp values ranging from 2.7 to 3.0 μmwere calculated. In
each case, the FPF calculated on the actual amount of C109
deposited on NGI cups with a cutoff diameter of less than
5.39 μm (cups 3-7) was ≥40%, with a maximum value ~48% in
the case of the eFlow Rapid pulmonary delivery device. With
respect to the emitted dose (RF in Table 2), this value increased
up to 75%.
Behavior of C109 nanocrystals in simulated lung fluids
In vitro release studies were performed by dialysis from
artificial CF mucus to SILF. A significantly increase of the
release rate was observed for TPGS_C109 aqueous formulation
and its dry TPGS_C109_CD0.5 and TPGS_C109_CD1.0
counterparts as compared to raw C109 (Figure 4, A), with
90%-95% of the initial amount of C109 added to artificial mucus
available in SILF after only 2 h of incubation at 37 °C.
SAXS investigation of the behavior of the TPGS_109
formulations incubated in artificial CF mucus has been also
performed by mixing the 10 mg/mL nanosuspensions and the
model mucus in 1:3 v/v ratio. SAXS spectra were then acquired
after 1 h incubation at room temperature. The reconstruction
of the spectrum of the mixed system (Figure 4, B, black line) by
linear combination of the artificial CFmucus (green squares) and
the nanosuspension (blue squares) shows nice overlappingwith the
experimental profile (pink circles), except for a moderate decrease
of the slope at very low-q. Similar experiments were performed by
SAXS analysis of TPGS_C109 and TPGS_C109_CD0.5 formu-
lations (Figure S3). Complementary studies were performed by
SANS, allowing to exploit different contrast with respect to X-ray
scattering. Figure 4, C shows the comparison of the SANS spectra
of the initial nanocrystal formulations with the profile obtained
after interaction with a 2% w/v dispersion of mucin by subtracting
Figure 3. In vitro aerosol performance of TPGS_C109_CD0.5 and TPGS_C109_CD1.0 dry powders for inhalation suspension. Cumulative mass recovered as a
function of the cutoff diameter (A) and NGI deposition pattern (B) upon delivery through the Aeroneb® Go nebulizer. Cumulative mass recovered as a function
of the cutoff diameter (C) and NGI deposition pattern of TPGS_C109_CD1.0 formulation upon delivery through different nebulizers (D). The formulation was
delivered through PARI TurboBOY® (PARI GmbH, Germany), Aeroneb® Go (Aerogen, Ireland) and eFlow® Rapid (PARI GmbH, Germany) after
reconstitution in an appropriate amount of water. Data are presented as mean ± standard deviation (SD) (n = 3).
Table 2
Fine particle characteristics of the aerosol clouds generated upon delivery of
the TPGS_C109_CD1.0 dry powders for inhalation suspension through
different nebulizers.
Aeroneb® Go PARI TurboBOY® eFlow® rapid
MMADexp
1 (μm ± SD) 3.04 ± 0.280 2.72 ± 0.650 2.94 ± 0.220
GSD1 (± SD) 2.30 ± 0.060 2.83 ± 0.30 2.30 ± 0.016
FPF2 (% ± SD) 41.9 ± 3.60 39.3 ± 4.60 47.7 ± 8.50
RF2 (% ± SD) 63.7 ± 2.60 68.8 ± 11.6 75.0 ± 5.10
1 Experimental MMAD and geometrical standard deviation (GSD) were
calculated from the logarithmic linear regression according to European
Pharmacopoeia.
2 Percentage of particles with a MMAD lower than 5 μm. Fine Particle
Fraction (FPF) was calculated on the nominal C109 dose, whereas the
Respirable Fraction (RF) refers to the emitted dose of C109.
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systems. Of note, destructive effects of interaction with mucus are
visible at larger scale, that is on the size of the nanocrystal. Indeed,the decrease at low q of the reconstructed difference profiles may
indicate the reduction of large-scale aggregates at the time of
measurement. The intensity decrease can also be associated to
other effects such as a decreased correlation of the mucin mesh.
However, this is unlikely to occur down to distances of 80 nm
(q ~ 0.08 nm−1) (Figure 5, B). Thus, in line with release studies,
SANS data suggest that the nanocrystals undergo partial dissolution
upon incubation in mucin: the stronger effect of deconstruction
seen in SANS with respect to SAXS can be due to the longer
incubation time before analysis.
To definitively prove the ability of C109 nanocrystals to
diffuse in mucus, a SAXS study of particle horizontal migration
(horizontal 1D self-diffusion) was performed. Macroscopic
mobility of the nanocrystal was studied in the same plastic
capillaries used for structural investigation by inserting artificial
CF mucus from one edge of the capillary and the particle
dispersion from the other side (Figure 5, A). After 6 h of contact,
SAXS spectra were collected by horizontal scanning of the
capillary along its length (Figure 5, B). At this delay time, it was
Figure 4. Behavior of nanocrystals in lung lining fluids. (A) In vitro release
profile of C109 from artificial CF mucus to SILF at 37 °C. Data are
presented as mean value ± SD (n = 3). (B) SAXS spectra of artificial CF
mucus spectrum (green empty squares), TPGS_C109 (blue empty squares)
and TPGS_C109_CD1.0 in artificial CF mucus (pink empty squares). The
black lines show the spectrum reconstructed by summing the contributions
of artificial CF mucus and TPGS_C109 CD1.0. (C) SANS spectra of
TPGS_C109 (triangles) and TPGS_C109_CD1.0 (squares) in the 2% w/v
mucin dispersion. Empty symbols are spectra of nanocrystals in water
dispersion and full symbols are the spectra of the same formulations in
mucin after subtraction of mucin spectral contribution to the scattered
intensity.
Figure 5. SAXS-assisted horizontal migration studies performed on
TPGS_C109_CD1.0. (A) Capillary withmucus on the left and nanosuspension
on the right during migration. Arrow indicates the direction of migration; bars
are the color codes for spectra sequence shown in panel B. (B) Representative
spectra upon a horizontal scan of the capillary from left to right. The red
spectrum corresponds to a position with prevalence of low-q nanocrystal
contribution with respect to the next right-side blue spectrum; triangles
correspond to a spectrum taken at a longer delay after contact showing similar
high-q contribution as the orange spectrum but a lower intensity at low-q
(see discussion in the main text). The inset shows the low-q region scattered
intensity in linear scale.
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moving with different velocities. The detection of the different
components is performed by an analysis of the SAXS spectra
collected at different distances from the mucus-particles initial
contacting interface. The horizontal migration of the nanocrystal
has a typical rate of 10 μm/min. More precise quantification is
difficult due to the evolution of the nanosuspension scattering
profiles during migration.
From a careful analysis of the spectra, the nanocrystal profile
rises along the capillary far from the first contact interface. This
is evident from the orange bold SAXS spectrum of 5, B, taken at
about 5 mm distance from the initial mucus–particles interface:
in the low-q region of the spectrum the excess scattered intensity
with respect to that of sole artificial mucus is a sign of the
nanocrystal presence. Reversely, the high q region of
the spectrum corresponds to the amount of TPGS and CD. The
amount of these last components is higher at lower migration
distances from the initial interface of contact (bold blue line) and
Figure 6. Inhibition (A) and eradication (B) ability of C109, TPGS_C109
or TPGS_C109_CD1.0 against B. cenocepacia J2315 biofilm. Data shown
are the mean number of CFU recovered after no treatment (CTRL) or
treatment with C109 (8 μg/mL) in DMSO (C109), TPGS_C109 or
TPGS_C109_CD1.0. Error bars are SD calculated on triplicate experiments
(n = 3). Data were analyzed by using a one-way ANOVA, with a Scheffe
post hoc test (*P b 0.05 versus CTRL, **P b 0.05 versus C109).
Table 3
MIC determination (μg/ml) of C109 nanocrystal-embedded dry powders
compared to C109.
Strain TPGS_C109_CD0.5/
TPGS_C109_CD1.0
C109 Reference
B. cenocepacia J2315 8 8 Lab strain
B. cenocepacia K56-2 8 8 Lab strain
B. cenocepacia 451 (III-A) 4 4 10
B. cenocepacia 1232 (III-A) 8 8 10
B. cenocepacia 3167 (III-A) 16 32 10
B. cenocepacia FCF13 (III-A) 32 32 10
B. cenocepacia FCF14 (III-A) 8 8 10
B. cenocepacia FCF22 (III-B) 128 256 10
B. cenocepacia FCF23 (III-B) 16 16 10
B. cenocepacia FCF24 (III-B) 8 4 10
B. cenocepacia FCF27 (III-B) 8 4 10
B. cenocepacia FCF36 (III-D) 16 16 10
E. coli ATCC25922 4 8 11
A. baumannii ATCC 19606 8 16 11
S. aureus ATCC25923 2 4 11
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gradient. However, bold blue line also shows a lower intensity
at low-q with respect to the orange one, possibly suggesting
unbalanced contributions of the components, that is, uneven
migration rates between the large nanocrystals and the small
free components. Considering the 30% polydispersity in size of
the nanocrystals in suspension, the entire set of data would be
explained by assuming a counterintuitive higher diffusivity of
crystals with larger sizes.
Finally, Figure 5, B shows a representative spectrum from
a last scan of the capillary after 10 h delay: the low-q excessscattering reported by the orange bold spectrum just discussed, is
no more seen. This observation provides further evidence of a
deconstruction of the nanocrystal after long time in artificial CF
mucus, consistently with SANS data.
Assessment of in vitro antimicrobial activity of C109 nanocrystals
The biological activity of the formulations was first assessed
against planktonic B. cenocepacia cultures. The MICs of free
C109, TPGS_C109_CD0.5 and TPGS_C109_CD1.0 were
identical (Table 3). Moreover, time-kill curves of B. cenocepacia
J2315 in the presence of C109 dissolved in DMSO or of
formulated C109 are identical (Figure S4).
To further confirm the effectiveness of TPGS_C109_CD0.5
and TPGS_C109_CD1.0, MICs were determined also against a
panel of B. cenocepacia clinical isolates representative of three
genomovars (III-A, B, and D). The results were perfectly
comparable to the one of the C109 compound dissolved in
DMSO (Table 3). Also, the MICs of the formulations were
determined for other Gram-negatives (Escherichia coli, Acine-
tobacter baumannii) and the Gram-positive Staphylococcus
aureus, achieving the same results (Table 3).
It is noteworthy that B. cenocepacia can form biofilm, thus
rendering the treatment of infections much more difficult. We
compared the ability of C109, TPGS_C109 and freeze-dried
powders containing the highest amount of CD (i.e., TPGS_
C109_CD1.0) to inhibit and eradicate biofilms at a concentration
of 8 μg/ml (Figure 6). When it comes to inhibiting B. cenocepacia
J2315 biofilms, C109 and TPGS_C109 resulted in a significant
(*P b 0.05 versus CTR) approximately 100-fold (2 log) reduction
of CFU/biofilm, while TPGS_C109_CD1.0 resulted in a 4-log
reduction of CFU/biofilm as compared to C109 (**P b 0.05
versus C109) (Figure 6, A). Nevertheless, none of the compounds
was able to eradicate the biofilm (Figure 6, B).
Cytotoxicity of C109 nanocrystals to CF bronchial epithelial cells
The cytotoxicity of the different C109 formulations against a
wild type (16HBE) and a CF bronchial epithelial (CFBE41o−)
Figure 7. Cytotoxicity of C109 formulations to wild type 16HBE (A) and
CF (CFBE41o−) bronchial epithelial cells (B). Data are presented as mean
value ± SD calculated on triplicate experiments (n = 3).
Figure 8. Kaplan–Meier survival-curve of infected G. mellonella receiving
no treatment (black) or a treatment with piperacillin (red), the formulation
TPGS_C109 (blue) or the combination piperacillin plus TPGS_C109_CD
(green). ** P b 0.01; * P b 0.05. Survival curves were analyzed by using a
log-rank (Mantel–Cox) test.
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the toxic concentration at 50% (TC50) of C109 on these cell lines
is about 75 μM.11 C109 nanocrystals showed the same behavior
as C109 compound in 16HBE cells (Figure 7, A), while the
TC50 of TPGS_C109 was greater than 100 μM in CFBE41o−
cells (Figure 7, B). The corresponding controls, TPGS and CD
alone (Figure 7), as well as the combination of CD and TPGS
(data not shown) did not cause significant toxicity. Of note,
the TC50 of C109 and the corresponding TPGS_C109_CD1.0
was at least 3-fold higher than the microbiologically active
concentration of the compound on the most sensitive bacterial
strains, that is 13.5-27 μM (4–8 μg/mL) (Table 1). No
differences were apparent between TPGS_C109_CD0.5 and
TPGS_C109_CD1.0 (data not shown).
In vivo antimicrobial activity of C109 nanocrystals
The in vivo antimicrobial activity of the formulation alone
or in combination with piperacillin, previously demonstrating
in vitro additive interaction with C109 against K56-2,11 was
investigated.
Neither C109 or the formulation, or the antibiotic was toxic
for G. mellonella at the concentrations used (data not shown).
Larvae succumbed to the infection upon treatment with PS,
DMSO, TPGS, C109 (data not shown) or TPGS_C109 orreceiving no treatment (Figure 8) by 72 h post-infection (p.i.).
On the contrary, when treated with piperacillin or the
combination of piperacillin and TPGS_C109 survival was
significantly increased after 48 and 72 h p.i. (Figure 8).
Interestingly, the highest survival rate was achieved using the
combination TPGS_C109 plus piperacillin (75% survival versus
52% of the piperacillin alone after 48 h, and 20% versus 10%
after 72 h). The same result was not achieved when C109
compound was used in combination with piperacillin (data not
shown).
These observations were confirmed by measuring the
bacterial load (CFU/larva) at 48 and 72 h p.i.in the hemolymph
of two larvae/group: only upon treatment with piperacillin alone
or the combination piperacillin plus TPGS_C109 was the
bacterial load significantly reduced (data not shown).Discussion
B. cenocepacia is a resistant Gram-negative bacterium,
carrying a worse prognosis and posing substantial therapeutic
challenges to CF sufferers.4 In this work, we propose an
inhalable formulation for lung delivery of the poorly water-
soluble FtsZ inhibitor C109, with promising activity against
B. cenocepacia.10 ,11
Pulmonary delivery of poorly soluble actives may generate
bioavailability and efficacy problems. Once deposited at lungs,
undissolved drug particles are either cleared by the mucociliary
escalator or phagocytized by alveolar macrophages.35 Here, the
reduction of particle size to the nanometer scale by nanoprecipita-
tion increases surface C109 area exposed to lung lining fluids and
drug saturation solubility at the solid surface. Nevertheless, the
presence of TPGS was necessary to stabilize nanocrystal surface.
TPGS is a generally recognized as safe water-soluble derivative
of natural vitamin E,36 the application of which encompasses also
the stabilization of inhalable nanosuspensions.37–39 Furthermore,
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of PEG onto the nanocrystalline surface, likely contributing to
nanosuspension stability via steric hindrance.34,40
Despite the stabilizer, nanocrystal growth in the nanosuspen-
sion is unavoidable due to the complex interplay of thermody-
namics and molecular kinetics.41 ,42 Hence, crystal growth or
agglomeration can occur not only for the large interfaces and the
high Gibbs free energy of the disperse system, but also due to
Ostwald ripening effects.41 Thus, drying of the liquid nanocrys-
tal formulation is often required in conjunction with stabilizers
to obtain long term stability.42 To this purpose, the aqueous
dispersion of C109 nanocrystals was further processed by freeze-
drying to achieve a dry powder that could be reconstituted before
use, that is “nanocrystal-embedded dry powders”. However, the
dehydration process may induce stresses to nanocrystals, which
can be mitigated by the use of appropriate cryoprotectants.43 In
line with previous studies,24,44 CD represented a valid tool to
stabilize the PEGylated nanoparticulate system during freeze-
drying, since it may also promote PEG chain extension on
nanocrystal surface.25 Notably, the colloidal properties of the
system and the shell architecture were not affected by the
lyophilization cycle. The shell thickness slightly increased in the
presence of CD, likely due to its potential interactions with PEG
chain.45 Furthermore, WAXS analyses confirmed that the typical
crystal distances of raw C109 are not altered in the particle
production process.
The ability of the developed nanosuspension to assist drug
deposition at lungs and to improve the solubility profile of C109
in lung lining fluids is the “conditio sine qua non” to advance
the formulation to further in vitro/in vivo studies. Regarding
lung deposition, nanosuspensions are commonly atomized
into fine droplets via an appropriate nebulizer.46 A critical
quality attribute of the formulation for an efficient pulmonary
deposition is the aerodynamic droplet size distribution, which
needs to be assessed and maintained across the different
inhalation devices.47 We demonstrated that the developed
nanosuspension may be efficiently delivered by both conven-
tional jet nebulizers and portable vibrating mesh nebulizers,
currently regarded as the first choice for development of new
inhaled products.48 Once deposited at lungs, a fast C109
dissolution in lung lining fluids can be likely expected based
on in vitro release data, suggesting also the ability of
nanocrystals to diffuse in the mucus gel layer. Results were
confirmed by SAXS-assisted diffusion studies, which defini-
tively highlighted the ability of C109 nanocrystals to diffuse in
the mucus model.
The diffusion inside an adhesive gel, such as mucus, occurs in
the presence of interaction forces between particle components
and the building blocks of the hydrogel mesh, that is mucins and
possibly DNA. The presence of a TPGS-derived brush PEG
shell on the nanocrystal surface can reduce particle adhesion
to mucin fibers found in the mucus mesh, thereby allowing the
particles to quickly diffuse through the interstitial fluids between
the fibers.21 Nevertheless, some shape concerns may play an
important role in promoting the diffusion of C109 nanocrystals,
especially in view of the large particle size compared to the
typical mucus mesh size (around 300 nm).49,50 Recently, rod-
like particle diffusivity in mucus was demonstrated to be higherthan that of spherical particles with a diameter equal to the rod
minor axis one.51 The ability to diffuse is enforced by a preferred
optimum aspect ratio of the elongated nanoparticles.52 In fact,
adhesive gel is thought to cause a jumping-diffusion path of
the diffusant that enables rod-like particles of optimized aspect
ratio to achieve higher diffusivity than spherical ones. A similar
behavior can be hypothesized for the large elongated C109
nanocrystals, for which the aspect ratio may play the role of the
selection parameter for diffusion inside the mucus mesh with a
defined porosity.
Based on the encouraging physico-chemical and technolog-
ical properties, C109 nanocrystals underwent further studies
aimed at assessing their in vitro toxicological profile on human
bronchial epithelial cells and antimicrobial activity against
B. cenocepacia. Results highlighted how the broad-spectrum
antimicrobial activity of C109 is maintained upon formulation
and at microbiologically active concentrations the nanocrystals
did not significantly affect the viability of both wild type and
CF human bronchial epithelial cells. We previously showed
that C109 was also effective at inhibiting biofilm formation of
B. cenocepacia, but less capable of eradicating cells residing
in established biofilms.11 Results confirmed that C109
nanosuspensions significantly inhibited B. cenocepacia biofilm
formation. Noteworthy, the inhibitory effect was much more
pronounced in case of CD-containing nanocrystal-embedded dry
powders. Based on previous evidences,53 a potential entrapment
of N-acyl homoserine lactones involved in bacterial quorum
sensing inside CD cavity, likely contributing to C109 biofilm
inhibitory activity, cannot be excluded.
A proof-of-concept of the in vivo potential of the C109
formulations in eradicating B. cenocepacia infections was finally
given through the well-assessed Galleria mellonella model.54
Results highlighted that neither the C109 compound nor
formulation was toxic for G. mellonella and confirmed the
biocompatibility of TPGS_C109 formulation in a complex
physiological environment. While neither the raw compound
nor the formulation was able to eradicate the B. cenocepacia
infection, a significant improvement in survival was observed
in larvae treated with both piperacillin and TPGS_C109. This
clearly indicates a synergistic effect with a well-established
drug and paves the way to the use of C109 nanocrystals as a local
treatment option for combined therapy of B. cenocepacia lung
infection.
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